Chemoinformaics analysis of Dihydroscandenolide
| Molecular Weight | 336.34 | nRot | 1 |
| Heavy Atom Molecular Weight | 316.18 | nRig | 21 |
| Exact Molecular Weight | 336.121 | nRing | 4 |
| Solubility: LogS | -2.252 | nHRing | 3 |
| Solubility: LogP | 1.359 | No. of Aliphatic Rings | 4 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 44 | No. of Aliphatic Hetero Cycles | 3 |
| No. of Heavy Atom | 24 | No. of Aromatic Carbocycles | 0 |
| nHetero | 7 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 2 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 20 | No. of Saturated Hetero Cycles | 2 |
| No. of Carbon atom | 17 | No. of Saturated Rings | 2 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 7 | No. of Arom Bond | 0 |
| nHA | 7 | APOL | 47.3399 |
| nHD | 0 | BPOL | 29.6121 |
| QED | 0.62 |
| Synth | 5.988 |
| Natural Product Likeliness | 2.633 |
| NR-PPAR-gamma | 0.923 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.056 |
| Pgp-sub | 0.003 |
| HIA | 0.013 |
| CACO-2 | -5.112 |
| MDCK | 0.0000531 |
| BBB | 0.839 |
| PPB | 0.719931 |
| VDSS | 0.892 |
| FU | 0.390516 |
| CYP1A2-inh | 0.019 |
| CYP1A2-sub | 0.142 |
| CYP2c19-inh | 0.019 |
| CYP2c19-sub | 0.846 |
| CYP2c9-inh | 0.019 |
| CYP2c9-sub | 0.199 |
| CYP2d6-inh | 0.01 |
| CYP2d6-sub | 0.208 |
| CYP3a4-inh | 0.095 |
| CYP3a4-sub | 0.558 |
| CL | 11.869 |
| T12 | 0.317 |
| hERG | 0.004 |
| Ames | 0.058 |
| ROA | 0.919 |
| SkinSen | 0.104 |
| Carcinogencity | 0.447 |
| EI | 0.017 |
| Respiratory | 0.236 |
| NR-Aromatase | 0.296 |
| Antiviral | Yes |
| Prediction | 0.765302 |